Disease damage and low bone mineral density: an analysis of women with systemic lupus erythematosus ever and never receiving corticosteroids.
about
Bone disease in newly diagnosed lupus nephritis patientsBone health in a nonjaundiced population of children with biliary atresia.Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis.Osteoporosis screening, prevention, and treatment in systemic lupus erythematosus: application of the systemic lupus erythematosus quality indicatorsGlucocorticoid-induced osteoporosis in rheumatic diseases.Role of Fas and Treg cells in fracture healing as characterized in the fas-deficient (lpr) mouse model of lupus.Bone mineral density and carotid atherosclerosis in systemic lupus erythematosus: a controlled cross-sectional study.Inflammatory rheumatic disorders and bone.Manifestations of systemic lupus erythematosus17-β Estradiol reduces atherosclerosis without exacerbating lupus in ovariectomized systemic lupus erythematosus-susceptible LDLr(-/-) mice.Validation of the systemic lupus erythematosus activity questionnaire in a large observational cohort.Measurement and meaning of markers of reactive species of oxygen, nitrogen and sulfur in healthy human subjects and patients with inflammatory joint disease.Osteoporosis and fractures in systemic lupus erythematosus.Menopause and Rheumatic Disease.Why targeted therapies are necessary for systemic lupus erythematosus.Incidence of and risk factors for non-vertebral and vertebral fracture in female Chinese patients with systemic lupus erythematosus: a five-year cohort study.Cross-sectional and longitudinal evaluation of bone mass and quality in children and young adults with juvenile onset systemic lupus erythematosus (JSLE): role of bone mass determinants analyzed by DXA, PQCT and QUS.Six-year follow-up study of bone mineral density in patients with systemic lupus erythematosus.miR-148a regulates osteoclastogenesis by targeting V-maf musculoaponeurotic fibrosarcoma oncogene homolog B.Prevalence and predictors of low bone density and fragility fractures in women with systemic lupus erythematosus in a Mediterranean region.Alterations of bone geometry, density, microarchitecture, and biomechanical properties in systemic lupus erythematosus on long-term glucocorticoid: a case-control study using HR-pQCT.ApoE-/-Fas-/- C57BL/6 mice: a novel murine model simultaneously exhibits lupus nephritis, atherosclerosis, and osteopenia.Influences on bone mineral density in Malaysian premenopausal systemic lupus erythematosus patients on corticosteroids.Age at natural menopause among patients with systemic lupus erythematosus.Disease Outcomes in Glucocorticosteroid-Naive Patients With Systemic Lupus Erythematosus.Validation of the Japanese version of the Systemic Lupus Activity Questionnaire that includes physician-based assessments in a large observational cohort.Prevalence of and risk factors for low bone mineral density in Japanese female patients with systemic lupus erythematosus.A comparison of patients' and physicians' assessments of disease activity using the Swedish version of the Systemic Lupus Activity Questionnaire.
P2860
Q28543032-DC40D98A-A9B0-4257-8E8B-0AF464BEB978Q33482826-2F415A0E-C248-49A3-87E8-553254475685Q34027495-77CFE221-AE0B-4D16-8731-C89AC60E040FQ34192060-9D5F3B3F-7B7C-4D55-AA4B-DECE83B112C2Q34394081-CC62820B-F8B4-4CD6-8574-6072C03EDF58Q35008584-BF8611F4-5690-4746-A6C3-991997700A4AQ35530495-869ADED9-087A-40EC-875F-7A44DAA8E68CQ35918747-A4D39A05-2CFC-4D73-BF46-887444FE9440Q36082627-2073D678-23DE-4051-BF0E-C9ECCACCE5D4Q36746168-01021F6E-B828-4A70-97FB-202BA1B00666Q37137321-D63ABE6D-1487-4A2F-9520-93D09CAE3E98Q37936500-F24B5E78-0E91-4E8A-B14A-9FA7C4A90EF6Q37972874-49CEDEDF-D8E5-4DBF-AD6F-312418D02269Q38846584-4A84E524-6CCF-4FB7-8935-DC32C68090B2Q38920435-AAE1A3EA-AB9D-4E66-B004-5A9BCE1A9AD9Q43817716-95AFA55C-B1E4-4DB6-B970-AB4F23529D7DQ44022058-E2F14E5B-E695-478C-8EE8-37E76323671EQ44427353-140F7CAE-2E22-4DFE-AA52-9FB04DE9AE35Q44756288-8A6E9126-815D-4FC5-9653-533A0FA45B54Q45418265-FF728A6F-EBAC-43A5-856D-E07277CDC10AQ45764489-038C60E5-C247-42FF-9A39-5BBD161F5589Q46014277-AA3ECA14-4947-4086-8648-94A63CE48C82Q46158711-D13850AC-A862-4133-A00D-BDBC351C4ECBQ46554198-C7FE8C87-6F3E-4E6B-8986-D87B09378699Q47790587-A6405102-D145-4356-BF69-5F4378481052Q47960264-94168545-CF8D-4862-8830-9B32A0B5FC7EQ51597128-CA01F4CF-DEAD-488B-A944-DAFED3724FB8Q54714606-EEA9765D-E94C-460A-988F-84EE891A2A1D
P2860
Disease damage and low bone mineral density: an analysis of women with systemic lupus erythematosus ever and never receiving corticosteroids.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Disease damage and low bone mi ...... ver receiving corticosteroids.
@en
Disease damage and low bone mi ...... ver receiving corticosteroids.
@nl
type
label
Disease damage and low bone mi ...... ver receiving corticosteroids.
@en
Disease damage and low bone mi ...... ver receiving corticosteroids.
@nl
prefLabel
Disease damage and low bone mi ...... ver receiving corticosteroids.
@en
Disease damage and low bone mi ...... ver receiving corticosteroids.
@nl
P2093
P356
P1433
P1476
Disease damage and low bone mi ...... ver receiving corticosteroids.
@en
P2093
Ramsey-Goldman R
P356
10.1093/RHEUMATOLOGY/KEI079
P577
2005-11-08T00:00:00Z